PL3296319T3 - Sposoby leczenia nowotworu jelita grubego - Google Patents
Sposoby leczenia nowotworu jelita grubegoInfo
- Publication number
- PL3296319T3 PL3296319T3 PL17197865T PL17197865T PL3296319T3 PL 3296319 T3 PL3296319 T3 PL 3296319T3 PL 17197865 T PL17197865 T PL 17197865T PL 17197865 T PL17197865 T PL 17197865T PL 3296319 T3 PL3296319 T3 PL 3296319T3
- Authority
- PL
- Poland
- Prior art keywords
- colon
- methods
- treating cancer
- cancer
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/595—Gastrins; Cholecystokinins [CCK]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29361210P | 2010-01-08 | 2010-01-08 | |
| US36785510P | 2010-07-26 | 2010-07-26 | |
| PCT/EP2011/000046 WO2011083088A2 (en) | 2010-01-08 | 2011-01-07 | Methods for treating colorectal cancer |
| EP11704178.0A EP2542585B8 (en) | 2010-01-08 | 2011-01-07 | Methods for treating colorectal cancer |
| EP17197865.3A EP3296319B1 (en) | 2010-01-08 | 2011-01-07 | Methods for treating colorectal cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3296319T3 true PL3296319T3 (pl) | 2021-09-27 |
Family
ID=43795093
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17197865T PL3296319T3 (pl) | 2010-01-08 | 2011-01-07 | Sposoby leczenia nowotworu jelita grubego |
| PL11704178T PL2542585T3 (pl) | 2010-01-08 | 2011-01-07 | Sposoby leczenia nowotworu jelita grubego |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11704178T PL2542585T3 (pl) | 2010-01-08 | 2011-01-07 | Sposoby leczenia nowotworu jelita grubego |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9217032B2 (pl) |
| EP (2) | EP2542585B8 (pl) |
| JP (1) | JP5930972B2 (pl) |
| KR (1) | KR101493261B1 (pl) |
| CN (1) | CN102947337B (pl) |
| AU (1) | AU2011204651B2 (pl) |
| BR (1) | BR112012016823A2 (pl) |
| CA (1) | CA2786417C (pl) |
| EA (1) | EA026944B1 (pl) |
| ES (2) | ES2875475T3 (pl) |
| NZ (1) | NZ601584A (pl) |
| PL (2) | PL3296319T3 (pl) |
| SG (1) | SG182335A1 (pl) |
| WO (1) | WO2011083088A2 (pl) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7854932B2 (en) | 2006-12-19 | 2010-12-21 | The Board Of Regents Of The University Of Texas System | Immunogenic compositions comprising progastrin and uses thereof |
| US8136651B2 (en) * | 2007-12-14 | 2012-03-20 | The Procter & Gamble Company | Method and apparatus for orienting articles |
| WO2011078301A1 (ja) | 2009-12-25 | 2011-06-30 | ファーマロジカルズ・リサーチ プライベート リミテッド | Nog樹立癌細胞株が移植された非ヒト動物モデルを用いた抗癌剤ターゲット探索及びスクリーニング法 |
| ES2754774T3 (es) * | 2010-03-24 | 2020-04-20 | Progastrine Et Cancers S A R L | Profilaxis de cáncer colorrectal y gastrointestinal |
| CA2806157C (en) * | 2010-07-26 | 2016-11-22 | Les Laboratoires Servier | Methods and compositions for liver cancer therapy |
| JP6230789B2 (ja) | 2010-10-06 | 2017-11-15 | 中外製薬株式会社 | 癌幹細胞集団及びその作製方法 |
| EP2715364A1 (en) * | 2011-06-01 | 2014-04-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for predicting the risk of developing a colonic neoplasia |
| JP6077997B2 (ja) * | 2011-09-07 | 2017-02-08 | 中外製薬株式会社 | 癌幹細胞の分離 |
| US20140302511A1 (en) | 2011-10-28 | 2014-10-09 | Pharmalogicals Research Pte. Ltd. | Cancer stem cell-specific molecule |
| WO2014116833A2 (en) * | 2013-01-23 | 2014-07-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Compositions and methods for detecting neoplasia |
| WO2016066671A1 (en) * | 2014-10-29 | 2016-05-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for treating resistant cancers using progastrin inhibitors |
| SI3227339T1 (sl) | 2014-12-05 | 2022-02-28 | Memorial Sloan-Kettering Cancer Center | Himerni antigenski receptorji, ki ciljajo na receptor, povezan z G-proteinom, in njihova uporaba |
| EP3227324A4 (en) | 2014-12-05 | 2018-08-29 | Memorial Sloan Kettering Cancer Center | Antibodies targeting g-protein coupled receptor and methods of use |
| JP6940505B2 (ja) * | 2015-12-31 | 2021-09-29 | シンセラス、エス、アー エル、エルＳｙｎｃｅｒｕｓ Ｓ．Ａ Ｒ．Ｌ． | 組成物および癌の発生リスクの評価方法 |
| SG11201805605TA (en) | 2015-12-31 | 2018-07-30 | Progastrine Et Cancers S A R L | Compositions and methods for detecting and treating ovarian cancer |
| JP7018885B2 (ja) * | 2015-12-31 | 2022-02-14 | プロガストリン、エ、カンセル、エス、アー エル、エル | 食道癌の検出および治療のための組成物および方法 |
| EP3954998B1 (en) | 2015-12-31 | 2024-12-25 | ECS-Progastrin SA | Compositions and methods for detecting and treating gastric cancer |
| CN110662769B (zh) * | 2017-03-30 | 2023-10-20 | 普莱戈斯瑞恩癌症有限责任公司 | 使用前胃泌素结合分子检测和治疗前列腺癌的组合物和方法 |
| US11561225B2 (en) | 2017-03-30 | 2023-01-24 | Progastrine Et Cancers S.À R.L. | Compositions and methods for treating lung cancer |
| DK3720879T3 (da) * | 2017-12-05 | 2022-06-20 | Progastrine Et Cancers S A R L | Kombinationsterapi mellem anti-progastrin-antistof og immunterapi til behandling af cancer |
| CN111670247B (zh) * | 2017-12-08 | 2024-01-05 | 京诊断株式会社 | 制备癌球状体的方法和选择结直肠癌患者的方法 |
| WO2019110845A1 (en) | 2017-12-08 | 2019-06-13 | Ecs-Biotracker Sàrl | Radiolabeled progastrin in cancer diagnosis |
| WO2019145537A1 (en) | 2018-01-26 | 2019-08-01 | Ecs-Progastrin Sa | Combination of progastrin detection with other cancer biomarkers in cancer diagnosis |
| AU2019228339B2 (en) | 2018-02-27 | 2025-02-27 | Ecs-Progastrin Sa | Progastrin as a biomarker for immunotherapy |
| KR20220122656A (ko) | 2019-12-06 | 2022-09-02 | 주노 쎄러퓨티크스 인코퍼레이티드 | Ｇｐｒｃ5ｄ-표적화 결합 도메인에 대한 항-이디오타입 항체 및 관련 조성물 및 방법 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| AUPO982097A0 (en) * | 1997-10-15 | 1997-11-06 | University Of Melbourne, The | Methods and compositions for use therein |
| AU2001249548A1 (en) * | 2000-03-27 | 2001-10-08 | Thomas Jefferson University | Compositions and methods for identifying and targeting cancer cells |
| US20050074793A1 (en) | 2003-04-04 | 2005-04-07 | Wilson Keith E. | Metastatic colorectal cancer signatures |
| KR101333168B1 (ko) | 2004-09-22 | 2013-11-28 | 리셉터 바이오로직스 인크 | 프로가스트린에 대한 모노클로날 항체 |
| ES2727306T3 (es) * | 2006-05-22 | 2019-10-15 | Inst Nat Sante Rech Med | Inhibidores de progastrina en el tratamiento del cáncer de colon |
| US7854932B2 (en) | 2006-12-19 | 2010-12-21 | The Board Of Regents Of The University Of Texas System | Immunogenic compositions comprising progastrin and uses thereof |
| WO2009099649A1 (en) | 2008-02-08 | 2009-08-13 | Poniard Pharmaceuticals, Inc. | Use of picoplatin and bevacizumab to treat colorectal cancer |
| US20090275546A1 (en) * | 2008-04-10 | 2009-11-05 | Istituto Superiore Di Sanita | Diagnostic tests and personalized treatment regimes for cancer stem cells |
| WO2010037395A2 (en) | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
-
2011
- 2011-01-04 US US12/984,532 patent/US9217032B2/en not_active Expired - Fee Related
- 2011-01-07 EA EA201201000A patent/EA026944B1/ru not_active IP Right Cessation
- 2011-01-07 CN CN201180013039.1A patent/CN102947337B/zh not_active Expired - Fee Related
- 2011-01-07 EP EP11704178.0A patent/EP2542585B8/en active Active
- 2011-01-07 ES ES17197865T patent/ES2875475T3/es active Active
- 2011-01-07 PL PL17197865T patent/PL3296319T3/pl unknown
- 2011-01-07 PL PL11704178T patent/PL2542585T3/pl unknown
- 2011-01-07 BR BR112012016823A patent/BR112012016823A2/pt not_active Application Discontinuation
- 2011-01-07 EP EP17197865.3A patent/EP3296319B1/en not_active Not-in-force
- 2011-01-07 AU AU2011204651A patent/AU2011204651B2/en not_active Ceased
- 2011-01-07 WO PCT/EP2011/000046 patent/WO2011083088A2/en not_active Ceased
- 2011-01-07 KR KR1020127020836A patent/KR101493261B1/ko not_active Expired - Fee Related
- 2011-01-07 SG SG2012049185A patent/SG182335A1/en unknown
- 2011-01-07 NZ NZ601584A patent/NZ601584A/en not_active IP Right Cessation
- 2011-01-07 CA CA2786417A patent/CA2786417C/en not_active Expired - Fee Related
- 2011-01-07 ES ES11704178.0T patent/ES2657458T3/es active Active
- 2011-01-07 JP JP2012547492A patent/JP5930972B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| SG182335A1 (en) | 2012-08-30 |
| EP3296319A1 (en) | 2018-03-21 |
| JP2013516437A (ja) | 2013-05-13 |
| CN102947337A (zh) | 2013-02-27 |
| CN102947337B (zh) | 2016-06-01 |
| EA201201000A1 (ru) | 2013-02-28 |
| EA026944B1 (ru) | 2017-06-30 |
| EP2542585A2 (en) | 2013-01-09 |
| KR20130028049A (ko) | 2013-03-18 |
| ES2875475T3 (es) | 2021-11-10 |
| KR101493261B1 (ko) | 2015-02-16 |
| WO2011083088A2 (en) | 2011-07-14 |
| JP5930972B2 (ja) | 2016-06-08 |
| NZ601584A (en) | 2014-11-28 |
| CA2786417A1 (en) | 2011-07-14 |
| BR112012016823A2 (pt) | 2017-09-26 |
| EP2542585B8 (en) | 2017-12-13 |
| CA2786417C (en) | 2016-03-29 |
| US20110177063A1 (en) | 2011-07-21 |
| EP2542585B1 (en) | 2017-10-25 |
| ES2657458T3 (es) | 2018-03-05 |
| AU2011204651B2 (en) | 2014-03-20 |
| AU2011204651A1 (en) | 2012-07-26 |
| PL2542585T3 (pl) | 2018-04-30 |
| HK1252832A1 (en) | 2019-06-06 |
| US9217032B2 (en) | 2015-12-22 |
| WO2011083088A3 (en) | 2011-10-20 |
| EP3296319B1 (en) | 2021-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289300A (en) | Combination therapy for treating cancer | |
| PL3296319T3 (pl) | Sposoby leczenia nowotworu jelita grubego | |
| IL276362A (en) | Cancer treatment methods | |
| IL262956B (en) | Methods for increasing efficacy of folr1 cancer therapy | |
| LT2707030T (lt) | Vėžio gydymas | |
| PL2552438T3 (pl) | Sposoby leczenia raka wątrobowokomórkowego | |
| PL2739153T3 (pl) | Leczenie raka sutka | |
| HUE047198T2 (hu) | Fitokannabinoidok emlõrák kezelésére | |
| IL224370B (en) | Combination treatment for prostate carcinoma | |
| HUE046667T2 (hu) | Rák kombinatív kezelése | |
| BR112014007603A2 (pt) | métodos de tratamento do câncer | |
| KR101839161B9 (ko) | 난소암의 치료를 위한 항혈관신생 요법 | |
| DK2717941T3 (da) | Behandling af cancer | |
| PT2897620T (pt) | Método de tratamento de cancro | |
| BR112012005594A2 (pt) | tratamento de câncer | |
| BR112013011659A2 (pt) | métodos de tratamento do câncer | |
| LT2914254T (lt) | Kombinacinės terapijos chemoresistencinių vėžių gydymui | |
| HUE045445T2 (hu) | Kombinált terápia petefészekrák kezelésére | |
| PL2742356T3 (pl) | Środki prognostyczne w leczeniu nowotworów | |
| EP2640390A4 (en) | METHODS OF TREATING CANCER | |
| DK2802351T3 (da) | Midler til behandling af triple-negativ brystkræft | |
| SI2892925T1 (sl) | Kombinacijsko zdravljenje raka | |
| PL2467140T3 (pl) | Lapatynib do leczenia raka | |
| EP2849786A4 (en) | Methods for treatment of gastric cancer | |
| EP2585115A4 (en) | Cancer therapy |